Published Technical Disclosure Archive

Enhanced Octreotide Delivery Systems for Acromegaly Treatment

Publication ID: 24-11857595_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Octreotide Delivery Systems for Acromegaly Treatment,” Published Technical Disclosure No. 24-11857595_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857595_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,595.

Summary of the Inventive Concept

This inventive concept improves the treatment of acromegaly by introducing novel oral formulations, monitoring devices, and personalized treatment approaches that enhance the efficacy, safety, and efficiency of octreotide delivery.

Background and Problem Solved

The original patent relates to oral drug delivery of octreotide for treating acromegaly. However, the existing patent has limitations in maintaining therapeutic levels of octreotide, predicting and adjusting dosage, and reducing side effects. This inventive concept addresses these limitations by introducing controlled-release formulations, machine learning algorithms, and co-administration of gut-friendly probiotics.

Detailed Description of the Inventive Concept

The inventive concept comprises four key aspects: 1) controlled-release oral formulations of octreotide designed to maintain therapeutic levels for an extended period; 2) a monitoring device for tracking IGF-1 levels and clinical symptoms; 3) machine learning algorithms for predicting and adjusting dosage based on individual patient responses; and 4) co-administration of gut-friendly probiotics to reduce side effects. These components work in tandem to provide personalized, efficient, and safe treatment of acromegaly.

Novelty and Inventive Step

The new claims introduce novel and non-obvious improvements over the original patent, including the use of controlled-release formulations, machine learning algorithms, and gut-friendly probiotics. These innovations provide a significant enhancement in the treatment of acromegaly, making the inventive concept a substantial improvement over the existing patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include different types of controlled-release formulations, such as nanoparticles or liposomes, or the use of wearable devices for real-time monitoring. Additionally, the inventive concept could be adapted for treatment of other diseases beyond acromegaly, such as diabetes or cancer.

Potential Commercial Applications and Market

The enhanced octreotide delivery systems have significant commercial potential in the pharmaceutical industry, particularly in the areas of rare diseases and personalized medicine. The target market includes pharmaceutical companies, hospitals, and research institutions focused on developing innovative treatments for acromegaly and other diseases.

CPC Classifications

SectionClassGroup
A A61 A61K38/08
A A61 A61K9/0053
A A61 A61K9/4858
A A61 A61K38/31
A A61 A61P5/06

Field of Art

Pharmaceutical drug delivery, specifically oral formulations for peptide hormones in endocrine disease treatment, requiring expertise in pharmaceutical chemistry, drug formulation, and medical device design

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist or biomedical engineer with advanced degree, experience in drug delivery systems, knowledge of peptide stability, formulation techniques, and understanding of endocrine disease management

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core innovation of oral octreotide delivery, utilizing standard pharmaceutical engineering techniques to enhance drug administration, monitoring, and personalization of treatment approaches.

Obvious Combinations & Variations

Source Patent Element
Oral octreotide dosage form with enterically coated capsule
PTD Variation
Controlled-release formulations using nanoparticles or liposomes
Obviousness Reasoning
Known drug delivery techniques for improving peptide stability and absorption, representing a predictable optimization of existing oral delivery method
Source Patent Element
Method of monitoring IGF-1 and clinical symptoms
PTD Variation
Machine learning algorithms for dosage prediction and adjustment
Obviousness Reasoning
Applying computational data analysis to existing clinical monitoring represents an obvious technological progression in personalized medicine
Source Patent Element
Oral administration of octreotide with H2-receptor antagonist
PTD Variation
Co-administration of gut-friendly probiotics to reduce side effects
Obviousness Reasoning
Standard pharmaceutical approach of mitigating gastrointestinal complications through complementary therapeutic agents
Source Patent Element
Oral dosage form of octreotide
PTD Variation
Wearable monitoring device for real-time IGF-1 and symptom tracking
Obviousness Reasoning
Integrating digital health technologies with existing pharmaceutical treatment represents a predictable innovation in patient care management
35 U.S.C. § 103 Summary: Based on US Patent 11857595's teachings of oral octreotide delivery, the present publication demonstrates that a Person Having Ordinary Skill In The Art would find the claimed variations obvious through standard pharmaceutical engineering techniques, representing anticipatory prior art that would render subsequent similar claims obvious through predictable technological extensions.

Original Patent Information

Patent NumberUS 11,857,595
TitleMethod of treating diseases
Assignee(s)Amryt Endo, Inc.